New treatment to help hemophilia patients manage immune responses
Official title: Immunocytokine therapy for immune modulation in hemophilia
Funded at Indiana University Indianapolis · NIH-11041250 · Data updated 2026-11-12
This study is looking at a new treatment that uses a special protein to help the immune system work better for people with hemophilia who have trouble with their clotting factor therapy, aiming to make their treatment easier and more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | January 1, 2025 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $582,638 |
| NIH project number | 1R33HL177497-01 |
| Project ID | NIH-11041250 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with hemophilia who have developed inhibitors against clotting factor replacement therapy.
✕Less likely to help
Patients who do not have hemophilia or those who have not developed inhibitors against clotting factors may not benefit from this research.
What this research studies
This research investigates a novel immunocytokine therapy aimed at improving immune tolerance in patients with hemophilia who develop inhibitors against clotting factor replacement therapy. The approach focuses on utilizing a specific cytokine, IL-2, to enhance the function of regulatory T cells, which are crucial for preventing the immune system from attacking the replacement therapy. By minimizing the adverse effects associated with current treatments, this therapy seeks to reduce the frequency of infusions and improve overall patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and less burdensome treatment option for hemophilia patients, reducing complications and improving their quality of life.
How similar studies have gone: While the approach of using immunocytokines is innovative, similar strategies targeting immune modulation in other conditions have shown promise, suggesting potential for success in this area as well.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Biswas, Moanaro — Indiana University Indianapolis
- Study coordinator: Biswas, Moanaro
Related research
Other NIH-funded projects on the same topics.
-
cGMP production of FVIII-making placental cells to help people with Hemophilia A
A new, patient-friendly therapy aims to make FVIII-producing placental cells in the lab to help adults with Hemophilia A, potentially offering a longer-lasting and more affordable treatment.
-
Enhancing immune regulation in gene therapy for hemophilia (new approaches to safer treatment)
A patient-focused overview of a long-running NIH grant exploring how to make gene therapy for hemophilia safer by teaching the body’s immune system to tolerate the therapeutic protein.
-
A safer, longer-lasting gene delivery approach for Hemophilia A using improved nonviral vectors
Researchers are testing a new type of nonviral gene delivery that could provide longer expression of a therapeutic gene for adults with Hemophilia A.
-
Non-viral gene therapy approach to permanently fix hemophilia B
A new gene therapy approach aims to permanently correct hemophilia B without using viruses, potentially reducing bleeding events for people with this condition.
-
Hemophilia Point-of-Care Test Gets Regulatory Ready
A new point-of-care test for hemophilia A measures FVIII and emicizumab to help doctors manage bleeding risk quickly, with plans to obtain regulatory clearance.
-
Hemophilia A: studying why some people develop inhibitors to FVIII across families
This NIH grant funds a multi-year program to follow families affected by severe hemophilia A to understand why some individuals develop antibodies against factor VIII.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.